No abstract

The SRAM cells are used in many applications where power consumption will be the main constraint. The Conventional 6T SRAM cell has reduced stability and more power consumption when technology is scaled resulting in supply voltage scaling, so other alternative SRAM cells from 7T to 12T have been proposed which can address these problems. Here a low power 7T SRAM cell is suggested which has low power consumption and condensed leakage currents and power dissipation. The projected design has a leakage power of 5.31nW and leakage current of 7.58nA which is 84.9% less than the 7T SRAM cell without using the proposed leakage reduction technique and it is 22.4% better than 6T SRAM and 22.1% better than 8T SRAM cell when both use the same leakage reduction technique. The cell area of the 7T SRAM cell is 1.25µM 2 , 6T SRAM is 1.079µM 2 and that of 8T SRAM is 1.28µM 2 all the results are simulated in cadence virtuoso using 18nm technology.

No abstract

Background: Joint health is very vital in canines. Immediate attention and diagnosis will help to prevent suffering in canines. This study was designed to evaluate the in vivo efficacy of the poly-herbal formulation Mobility Plus® for arthritis, inflammation and analgesic activities in canines. Methods: A total of 18 client-owned dogs with a history of joint inflammation, hip dysplasia and arthritis were selected (n = 18) and supplemented with one tablet of Mobility Plus® daily until complete recovery. The changes in assessment parameters scores, viz. lameness score, joint mobility score, pain on palpation score, weight-bearing score and the overall clinical condition score were evaluated. The results revealed that lameness, joint mobility, pain and weight-bearing scores significantly (p less than 0.001) decreased in dogs as early as day 15; hence, the overall clinical condition score also decreased significantly (p less than 0.001) as early as day 15 after Mobility Plus® supplementation. Result: Present study revealed that lameness, joint mobility, pain and weight-bearing scores significantly (p and lt; 0.001) decreased in dogs as early as day 15; hence, the overall clinical condition score also decreased significantly (p and lt; 0.001) as early as day 15 after Mobility Plus® supplementation. Supplementation of Mobility Plus® has antiarthritic and anti-inflammatory activities. Mobility Plus® could be recommended for the amelioration of joint inflammation and osteoarthritis conditions in canines.

No abstract